Expression of CYP2S1 in human hepatic stellate cells  by Marek, Carylyn J. et al.
FEBS Letters 581 (2007) 781–786Expression of CYP2S1 in human hepatic stellate cells
Carylyn J. Mareka, Steven J. Tuckera, Matthew Korutha, Karen Wallacea,b,
Matthew C. Wrighta,b,*
a School of Medical Sciences, Institute of Medical Science, University of Aberdeen, Aberdeen, UK
b Liver Faculty Research Group, School of Clinical and Laboratory Sciences, University of Newcastle, Newcastle, UK
Received 22 November 2006; revised 16 January 2007; accepted 23 January 2007
Available online 2 February 2007
Edited by Laszlo NagyAbstract Activated stellate cells are myoﬁbroblast-like cells
associated with the generation of ﬁbrotic scaring in chronically
damaged liver. Gene chip analysis was performed on cultured ﬁ-
brotic stellate cells. Of the 51 human CYP genes known, 13
CYP and 5 CYP reduction-related genes were detected with 4
CYPs (CYP1A1, CYP2E1, CY2S1 and CYP4F3) consistently
present in stellate cells isolated from three individuals. Quantita-
tive RT-PCR indicated that CYP2S1 was a major expressed
CYP mRNA transcript. The presence of a CYP2A-related pro-
tein and testosterone metabolism in stellate cell cultures suggest
that stellate cells express speciﬁc functional isoforms of CYP of
which a major form is CYP2S1.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Cytochrome P450s (CYPs) are membrane-associated heme-
thiolate proteins involved in the metabolism of both exogenous
and endogenous compounds [1]. CYPs primarily mediate the
mono-oxygenation of lipophilic substrates to increase their
polarity and to functionalise them for conjugation with water
soluble groups [1]. Most exogenous xenobiotics (drugs/toxins)
are metabolised by CYPs in the gene families 1–3, which are
expressed at high levels within hepatocytes (the main func-
tional cell of the liver) [1]. Other CYPs metabolise endogenous
lipophilic compounds such as steroids. High expression of
these isoforms is often restricted to non-hepatic tissues (e.g.
steroid synthesising tissues such as the adrenals and gonads)
[1].
Hepatic stellate cells (HSCs) are positioned in the space of
Disse in close proximity to hepatocytes. HSCs function to
store vitamin A esters in normal liver [2]. In response to
chronic hepatocyte damage, HSCs trans-diﬀerentiate/activate
into a myoﬁbroblast-like pro-ﬁbrogenic cell responsible forAbbreviations: AhR, aryl hydrocarbon receptor; CYP, cytochrome
P450; HSC, hepatic stellate cell
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doi:10.1016/j.febslet.2007.01.056the expression and accumulation of scarring extracellular
ﬁbrotic matrix protein [2]. It is currently thought an inhibition
of ﬁbrosis in liver diseases may be an eﬀective approach to
treating patients for which the cause is refractive to current
treatments (e.g. in approx. 30% of hepatitis C infected
patients) [2,3]. At present, there is no approved treatment for
ﬁbrosis.
Inadvertent toxicity of drugs is often associated with a ‘‘met-
abolic activation’’ by CYPs [1]. However, pro-drug activation
by CYPs is a feature that is employed clinically in the treat-
ment of certain cancers [4,5]. The expression of CYPs in HSCs
was therefore examined to determine whether there are HSC-
speciﬁc isoforms of CYP that could be used to speciﬁcally acti-
vate drugs in HSCs.2. Materials and methods
2.1. Cell isolation and culture
Human HSCs were isolated from the margins of resected liver tissue
essentially as described [6,7]. The initial cell isolations were free of
hepatocytes as judged by morphological examination and through
examination for the expression of hepatocyte markers such as albumin
and carbamyl phosphate synthase (data not included). HSCs were typ-
ically >90% pure as judged morphologically with Kupﬀer cells the pri-
mary contaminating cell type. HSCs were cultured in Dulbecco’s
modiﬁed Eagle Medium (DMEM) containing 4.5 g/l of glucose and
supplemented with 16% (v/v) fetal calf serum, 80 u/ml penicillin,
80 lg/ml streptomycin and 32 lg/ml gentamycin. HSCs were seeded
onto plastic culture dishes whereupon the cells underwent proliferation
and trans-diﬀerentiation between 7 and 14 days. The Kupﬀer cells did
not proliferate and by day 7–10, only activated (a-smooth muscle actin
positive) HSCs were present [6,7]. Human hepatocytes were obtained
from the UK Human Tissue Bank (Leicester, UK) and were cultured
in William’s Medium E as described [7] for 12–24 h prior to use. The
use of human liver cells for scientiﬁc research was approved by the
Grampian Regional Ethics and Trent Regional Ethics Committees
and was subject to informed patient consent.
2.2. RNA isolation and gene chip microarray
RNA was isolated from human HSCs preparations (quiescent – at
day 2 of culture, activated – after at least 14 days of culture) using Tri-
zol (Invitrogen). The expression of mRNAs from 2 HSC preparations
were separately screened using human genome HGU133 Plus 2.0
arrays essentially as outlined [6]. Semi-comparative CYP expression
in HSC RNA preparations from a further three separate donors was
determined by RT-PCR. Random hexamer-primed RNA was reverse
transcribed using MMLV (Promega, Southampton, UK) essentially
as previously described [8]. PCR primers for CYP expression were
designed so that all primer pairs for individual CYP transcript had
the same GC content (52.2%) and similar predicted melting tempera-
tures (see Table 1). Individual 25 ll PCR ampliﬁcations were per-
formed under identical conditions (20 mM Tris–HCl (pH 8.8 at
25 C), 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% (v/v)ation of European Biochemical Societies.
Table 1
Primer sequences used for RT-PCR
Human CYP
target mRNA
Primer sequence (US/DS) Fragment
ampliﬁed (bp)
CYP1A1 ACACCCTCCAGAGACAACAGGTA 298
AGTGAGACTACCTCTGTGCCAGT
CYP1A2 GATGATGCTGTTTGGCATGGGCA 325
TAGCAGCTTTAGCCAAGTGCAGG
CYP1B1 AAGGTGCTTGGAGTTTACCTGGC 156
CTCCGGTAGAAACACAATGAGGG
CYP2C9 TGCATGCAAGACAGGAGCCACAT 429
CGGCACAGAGGCAAATCCATTGA
CYP2E1 CCCGAGACACCATTTTCAGAGGA 229
AGAAACAACTCCATGCGAGCCAG
CYP2S1 ACCCCCAACCACTTGTCCACACA 223
TGAGGGTCCTCGTATGTCCAAAG
CYP4F3 AATATCCTTGGCAGGGCACGGTA 173
TGAATACAGGCACACACCACCAC
CYP4F11 CAGTGCGTTCTCTCTGTGACTCT 279
CAGCCAGACTTTCTGAGACAGGA
CYP7B1 GCCCATAGGACTAAACTACAGCC 251
GGGCTTTGTGACTAAGGACAAAC
CYP11B1 AAACGCCATAGACTGGGTTGCTG 235
AATGCAGGCAGTGCCCTCTTGAA
CYP20A1 CTCGTCCTTTATGCCCTTGGTGT 230
ACCTGTCCCTCCACAGAAAGTAG
CYP27B1 CTTTGAGAGGAAGGGTGAAGCCT 256
GGGGCAAACCCACTTAATAGTGG
CYP51A1 AGTGCTGGGATTACAGGCATGAG 271
CCATCTCATATAGTTAGGCCCCG
782 C.J. Marek et al. / FEBS Letters 581 (2007) 781–786Triton X-100, 0.1 mg/ml nuclease-free BSA, 200 lM dNTPs, 800 pM
upstream and downstream oligonucleotide primers and 1.5 u Pfu DNA
polymerase (Promega)) for 33 cycles (1 min 95 C, 1 min 43 C, 2 min
73 C) to generate a semi-relative comparison of CYP transcript
expression.
Selected quantitative transcript expression was examined after re-
verse transcription (using a Taqman reverse transcription kit (Applied
Biosystems)) using a PE Applied Biosystems ABI7700 and PE Applied
Biosystems Gene Expression Assay, incorporating sequence-speciﬁc
forward, reverse and ﬂuorescently labelled probes (see Table 2).
2.3. Western blotting
Cells were washed with ice-cooled phosphate-buﬀered saline (PBS)
(137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L phosphate, pH 7.4),Table 2
Taqman kits used for quantitative RT-PCR
Sequence ID target mRNA Reference sequence
CYP1A1 Hs00153120_m1
CYP1A2 Hs00167927_m1
CYP1B1 Hs00164383_m1
CYP2E Hs00559368_m1
CYP2S1 Hs00258076_m1
CYP3A4 Hs00604506_m1
CYP-reductase Hs00287016_m1
TGF-b1 Hs00171257_ml
18S rRNA Hs999999901_slharvested and total protein levels determined by the method of Lowry.
Western blotting was performed as previously outlined [8] using a
CYP2A (UT-F) anti-sera provided by Prof Guengerich (Vanderbilt
University School of Medicine, Nashville, Tennessee) [9]. Antibodies
to a-smooth muscle actin and CYP reductase were purchased from
Sigma Chemical Co (Poole, UK) and GE Healthcare Life Sciences
(Amersham, UK), respectively.
2.4. Testosterone hydroxylation
Human HSCs were incubated with 20 lM [4-14C] testosterone
(0.1 lCi/ml) – purchased from GE Healthcare Life Sciences (Amer-
sham, UK) – and incubated as outlined for general culture. At various
times, the medium was removed and the steroids were extracted twice
into ethylacetate (typical recoveries were 97%). The organic phase was
retained and dried under vacuum. Steroids were then re-dissolved in a
ﬁxed volume of ethylacetate and subjected to TLC analysis as outlined
[10]. Metabolites were identiﬁed by comparison to co-migrating
authentic standards (purchased from Steraloids, London, UK) and
quantitated by phosphorimaging.3. Results and discussion
Fig. 1 indicates that ﬁbrosis-related genes known to be
highly expressed in activated HSCs (collagen 1A1, TIMP1
and a-smooth muscle actin mRNAs [2]) are readily detected
by microarray screening. Fig. 1 also demonstrates that there
is signiﬁcant (10% the levels of ﬁbrosis-related gene) expres-
sion of genes associated with CYP reduction. CYP reductase is
essential for non-mitochondrial CYP and is present in addition
to both cytochrome B5 reductase and cytochrome B5, which
function in the saturation of fatty acids but may also provide
the second electron in the CYP catalytic cycle associated with
NADH synergism [1]. CYP has also been shown to be present
in mitochondria where it employs an alternative reducing
chain that uses ferrodoxin and ferrodoxin reductase [1].
Fig. 1 suggests that mRNA expression for these genes are of
a similar order to the CYP reductase mRNA. Fig. 2 shows that
of the 51 CYP genes present in the human genome (and pres-
ent on the genechip), up to 13 CYPs transcripts were detected
in HSCs.
To contribute to the validation of genechip data and to
determine whether the expression of a CYP transcript is likely
to be seen in HSCs from most individuals, RT-PCR was
employed to screen HSCs from three individuals. Fig. 3 shows
that CYP1A1 mRNA was present in all individuals whereas
CYP1A2 was not detected (conﬁrmed by quantitative
RT-PCR, see Fig. 4). CYP1B1 may not be expressed in all
individuals as this transcript was absent from one out of three
preparations (Fig. 3) despite being a major expressed transcript
(Fig. 4) in agreement with a previous report in rat HSCs [11].
CYP2C9 was not expressed (Fig. 3), emphasising the limita-
tions of genechip microarray studies and the need to validate
the data by other means. CYP2E1 was detected by RT-PCR
(Fig. 3) and was detected as a relatively low expressed tran-
script by quantitative RT-PCR (Fig. 4).
Fig. 3 demonstrates for the ﬁrst time, that human HSCs
express CYP2S1mRNA.Fig. 4 suggests that CYP2S1 is amajor
expressed CYP isoform in human HSCs along with CYP1B1.
The major hepatic CYP – CYP3A4 – has been reported to be
expressed in human HSCs [12]. We have demonstrated that
human HSCs express the PXR [6], which is known to regulate
CYP3A expression in hepatocytes [13]. Although the PXR is
transcriptionally functional in human HSCs, in our hands,
the PXR did not regulate CYP3A gene expression in HSCs.
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Fig. 1. Microarray expression of CYP-related and pro-ﬁbrogenic mRNAs in activated human HSCs. (A) Mean ﬂuorescence intensities from two
separate screens (AH27 and AH37) for b-actin and GAPDHmRNAs at three separate positions on the chip. (B) Percentage mean (AH27 and AH37)
ﬂuorescence readings for the indicated CYP-related and ﬁbrogenic transcripts.
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Fig. 2. Microarray expression of CYP mRNAs in activated human HSCs. Data are the mean percentage b-actin ﬂuoresence intensities from the two
separate (AH27 and AH37) screens.
C.J. Marek et al. / FEBS Letters 581 (2007) 781–786 783Figs. 4 and 5A conﬁrm that CYP3A4 was not expressed in the
human HSCs analysed and was not detected in HSC samples
isolated from 10 individuals (data not shown). The CYP3A4
gene is expressed in a highly variable fashion in hepatocytes
and therefore CYP3A4 may be present in some individuals
[12], though likely a minority.
Fig. 3 indicates that CYP4F3 but not CYP4F11 is expressed
in human HSCs. Other CYP isoforms detected by microarray –
CYP7B1, CYP20A1, CYP27B1 and CYP51A1 – whilst detect-
able in at least one further HSC preparation out of three,
are likely to be less abundant and not ubiquitously expressed
as observed for CYP2S1.
Fig. 5A shows that human HSCs up-regulate (4.6 fold) the
levels of CYP2S1 mRNA as they activate from the quiescentphenotype. Antibodies to CYP2S1 are currently not available
and therefore an antibody known to immunoreact with the
CYP2A protein was employed to establish whether CYP2S1
is translated into protein (isoforms such as CYP1B1 have been
reported to be un-translated in normal cells [14]). Fig. 5B shows
that CYP2A6 was expressed in quiescent HSCs and that as the
cells trans-diﬀerentiated to an activated phenotype (as judged
by a-smooth muscle actin expression [2]), expression was down
regulated and an immuno-related protein of higher electropho-
retic mobility expressed. The likely identity of this protein,
given that CYP2S1 mRNA is up-regulated (Fig. 5A) and
CYP2S1 was the only CYP2 family gene expressed in HSCs,
is CYP2S1. Fig. 5B also shows that CYP reductase was consti-
tutively expressed in HSCs. CYP reductase is essential for most
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784 C.J. Marek et al. / FEBS Letters 581 (2007) 781–786CYP related metabolism and the expression of this gene in
HSCs strongly supports the contention that HSCs express some
isoforms of functional CYP. Testosterone is a commonly used
probe substrate for CYP-mediated metabolism because it is
metabolised in numerous positions by various CYP proteins
[10]. Fig. 5C and D demonstrate that human HSCs metabolise
testosterone to several diﬀerent products. The proﬁle of metab-olites was markedly diﬀerent from the proﬁle generated from
hepatocytes (not shown) and suggests that – at least under these
conditions – HSC CYPmay predominantly reduce testosterone
to androstendione (ADD) and Dehydroepiandrosterone
(DHEA). CYP are able to mediate reduction reactions and
ADD is a commonly generated metabolite of testosterone from
many CYPs [10]. Testosterone was used as an experimental
probe for CYP metabolism and is typically used in vast excess
of its physiological concentration in vivo in this context. It is
probable that testosterone is not a physiological substrate for
HSC CYPs, however, these data indicate that the CYP within
HSCs is functional.
This report demonstrates that there are probably a restricted
number of CYP genes expressed in pro-ﬁbrogenic human
HSCs. Accordingly, isoforms consistently and highly expressed
in HSCs may be important for HSC function. CYP1 genes are
known to metabolise a number of carcinogenic xenobiotics
and to be regulated by the dioxin receptor (AhR). The endog-
enous function of the AhR and CYP1 genes remain unclear
but may be to regulate the levels of a compound generated
from tryptophan through light exposure [15–17]. The high
expression of CYP1B1 mRNA in human HSCs is also seen
in rodent HSCs [11]. CYP2E1 metabolises small metabolites
such as alcohol and acetone [1]. CYP2E is also notable for
the release of reactive oxygen species [18] which are known
to promote ﬁbrogenesis in HSCs [2,19]. CYP2S1 is a newly
identiﬁed CYP that has been shown to be expressed in skin
and epithelial cells of airway, cervix and bladder and to be
inducible by polyaromatic hydrocarbons, which act via the
Fig. 5. (A) Real time RT-PCR for CYP3A4 and CYP2S1 mRNA transcripts in quiescent and activated HSC preparations. RNA was isolated from
three separate preparations (AH31, AH60, AH61), quiescent – day 2; activated – between 14 and 24 days of culture. Samples were analysed as
outlined in Section 2. N/d, not detectable. Data are expressed as the mean and standard deviation from the three preparations after normalisation for
18S rRNA. *Signiﬁcantly diﬀerent (two tailed) from quiescent level using the Student’s t-test (P > 95%). (B) Induction of a CYP2A-related protein(s)
in activating human HSCs. Human HSCs were isolated (IC) and placed in culture for up to 24 days. Cell extracts were prepared at the indicated times
and subjected to Western blotting. Extracts (10 lg total protein/lane) were probed for the indicated proteins. Data are typical of three separate
experiments. (C) Metabolism of testosterone by human HSCs in culture. Human HSCs in culture for 21 days were incubated with testosterone as
outlined in Section 2. Samples of culture medium were analysed at the indicated times. A, typical TLC separation of testosterone and metabolites –
T0, analysis prior to contact with cells; at 96 h of incubation, comparison with or without cells demonstrating generation of metabolites requires cells.
(D) Timecourse for metabolite generation. The unidentiﬁed metabolite was low to undetectable in some experiments. 16a-OH-ADD, 16 alpha
hydroxyandrostenedione; 11a-OH-T, 11 alpha hydroxytestosterone. Data shown is one experiment typical of 5.
C.J. Marek et al. / FEBS Letters 581 (2007) 781–786 785AhR [20,21]. CYP2S1 has been reported to metabolise reti-
noids [20] which are present at high levels in HSCs. This is
the ﬁrst report that HSCs express the CYP4F3, which has been
shown to be expressed in neutrophils and to mediate the
metabolism of leukotrienes [22].
These data demonstrate for the ﬁrst time that human HSCs
express CYP2S1 and CYP4F3 and that human HSCs express
the CYP1B1 as observed in rat HSCs [11]. The expression of
the isoforms may be informative about the functional role(s)
of these genes and may also be used as anti-ﬁbrogenic targets
or activators of anti-ﬁbrogenic pro-drugs.
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